

## PAPER DETAILS

TITLE: Effects of Quadriceps Muscle Strength and Kinesiophobia on Health Related Quality of Life in Elderly Women and Men with Chronic Obstructive Pulmonary Disease

AUTHORS: Alp Ozel,Eylem Tutun Yumin,Tuncer Tug,Meral SERTEL

PAGES: 333-340

ORIGINAL PDF URL: <https://dergipark.org.tr/tr/download/article-file/558935>

# ORIGINAL ARTICLE

Alp Ozel<sup>1</sup>  
Eylem Tutun Yumin<sup>1</sup>  
Tuncer Tug<sup>2</sup>  
Meral Sertel<sup>3</sup>

<sup>1</sup>Bolu Abant İzzet Baysal  
University, School of Physical  
Therapy and Rehabilitation Bolu,  
Turkey

<sup>2</sup>Bolu Abant İzzet Baysal  
University, Department of Chest  
Diseases, Bolu, Turkey

<sup>3</sup>Kirikkale University, Faculty of  
Health Sciences, Department of  
Physiotherapy and Rehabilitation

## Corresponding Author:

Alp Özel  
Bolu Abant İzzet Baysal University,  
School of Physical Therapy and  
Rehabilitation, Bolu, Turkey  
Tel: +90 374 253 4661-4135  
E-mail: ptalpozel@gmail.com

Received: 15.12.2017  
Acceptance: 25.08.2018  
DOI: 10.18521/kt.365860

Konuralp Medical Journal  
e-ISSN1309-3878  
konuralptipdergi@duzce.edu.tr  
konuralptipdergisi@gmail.com  
www.konuralptipdergi.duzce.edu.tr

# Effects of Quadriceps Muscle Strength and Kinesiophobia on Health Related Quality of Life in Elderly Women and Men with Chronic Obstructive Pulmonary Disease

## ABSTRACT

**Objective:** The aim of this study was to investigate the effects of quadriceps muscle strength and kinesiophobia on health-related quality of life in elderly women and men with chronic obstructive pulmonary disease.

**Methods:** After recording the socio-demographic information of individuals, the Visual Analogue Scale (VAS) for pain status, the modified Medical Research Council Scale (mMRCs) for dyspnea, TAMPAscale for Kinesiophobia (TSK), Saint George Respiratory Questionnaire (SGRQ) for health-related quality of life, and manual dynamometer were used to measure for muscle strength of quadriceps.

**Results:** Seventeen (37.8%) of the 45 participants were female. The mean age and body mass index of females were 71.59±4.84 years and 28.75±6.71 kg/m<sup>2</sup>, respectively. Kinesiophobia averages were 47.47±7.40 and 41.89±7.65 in women and men, respectively, and SGRQ<sub>(Symptom)</sub> scores were 75.97±15.87 and 63.89±18.54 in women and men, respectively. Statistical analysis showed that there was a significant difference between men and women between kinesiophobia and SGRQ<sub>(Symptom)</sub> (p<0.05). There was a correlation between kinesiophobia and SGRQ<sub>(Activity)</sub>, SGRQ<sub>(Symptom)</sub> and SGRQ<sub>(Total)</sub> in females and kinesiophobia and SGRQ<sub>(Activity)</sub>, SGRQ<sub>(Impact)</sub> and SGRQ<sub>(Total)</sub> in males (p<0.05). The TSK score was found to affect the quality of life, more in women (p<0.05). There was no correlation between pain and quadriceps muscle strength and SGRQ parameters in both men and women (p>0.05).

**Conclusion:** In elderly individuals with COPD, kinesiophobia is an important factor affecting the quality of life and is recommended to increase physical activity, and monitor the physiological, emotional well-being in order to improve quality of life.

**Keywords:** COPD, Elderly, Kinesiophobia, Quadriceps Femoris, Quality of Life

# Kronik Obstrüktif Akciğer Hastalığı Olan Yaşlı Kadın ve Erkek Bireylerde Kuadriseps Kas Kuvveti ve Kinezyofobinin Sağlıkla İlgili Yaşam Kalitesi Üzerine Etkisi

## ÖZET

**Amaç:** Kronik obstrüktif akciğer hastalığı olan yaşlı kadın ve erkek bireylerde kuadriseps kas kuvveti ve kinezyofobinin sağlıkla ilgili yaşam kalitesi üzerine etkilerinin incelenmesi amaçlanmıştır.

**Gereç ve Yöntem:** Bireylerin sosyodemografik bilgileri kaydedildikten sonra, ağrı durumu için Vizüel Analog Skalası (VAS), dispne için modifiye Medical Research Council Skalası (mMRCs), kinezyofobi için TAMPAsölçeği (TKÖ), sağlıkla ilgili yaşam kalitesi için Saint George Solunum Anketi (SGSA) ve quadriceps kas kuvvetini ölçmek için manuel dinamometre kullanıldı.

**Bulgular:** Kırk beş katılımcının 17'si (37.8%) kadındı. Kadınların yaş ve vücut kütle indeksi ortalaması sırasıyla 71.59±4.84 yıl, 28.75±6.71 kg/m<sup>2</sup>, erkeklerin yaş ve vücut kütle indeksi ortalaması sırasıyla 72.14±5.66 yıl, 26.53±3.91 kg/m<sup>2</sup> idi. Kinezyofobi ortalamaları kadın ve erkeklerde sırasıyla 47.47±7.40 ve 41.89±7.65, SGSA<sub>(Semptom)</sub> skorları kadın ve erkeklerde sırasıyla 75.97±15.87 ve 63.89±18.54 idi. Yapılan istatistik analizde kadın ve erkeklerde, kinezyofobi ve SGSA<sub>(Semptom)</sub> arasında anlamlı fark olduğu gözlemlendi (p<0.05). Kadınlarda kinezyofobi ile SGSA<sub>(Aktivite)</sub>, SGSA<sub>(Semptom)</sub>, SGSA<sub>(toplam)</sub> arasında, erkeklerde kinezyofobi ile SGSA<sub>(Aktivite)</sub>, SGSA<sub>(Etki)</sub>, SGSA<sub>(Toplam)</sub> arasında ilişki bulundu (p<0.05). TKÖ skorunun kadınlarda daha fazla olmak üzere yaşam kalitesini etkilediği bulundu (p<0.05). Kadın ve erkeklerde ağrı ve quadriceps kas kuvveti ile SGSA parametreleri arasında ilişki gözlemlenmedi (p>0.05). **Sonuç:** KOAH'lı yaşlı bireylerde kinezyofobi yaşam kalitesini etkileyen önemli bir faktör olup, yaşam kalitesini arttırabilmek amacıyla fiziksel aktivitenin artırılması, fizyolojik, emosyonel iyilik halinin takibi tavsiye edilmektedir.

**Anahtar Kelimeler:** KOAH, Yaşlı, Kinezyofobi, Kuadriseps femoris, Yaşam kalitesi

## INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable pulmonary disease characterized by progressive airflow limitation in the airways and increased chronic inflammatory response in the airway. COPD is the fourth leading cause of death worldwide (1). Historically, the prevalence and mortality of COPD in men have been significantly greater than in women (2). This difference is largely due to differences in exposure to risk factors. The most well-known risk factor for the development of COPD is the consumption of tobacco products (3). The use of tobacco products is one of the major health problems in the world and in our country. One in four people in our country use tobacco products (4). The use of tobacco products is one of the preventable causes of illness (5).

Studies have emphasized that peripheral muscle weakness frequently occurs in individuals with COPD and that this affects daily life activities and quality of life negatively (6, 7). Systemic factors such as inflammation, hypoxia and nutritional insufficiency decrease the muscle activity level and cause muscle weakness with immobilization. Individuals with COPD are characterized by skeletal muscle weakness, decreased muscle strength, endurance, and is observed in approximately 32% of patients (8). Skeletal muscle weakness may lead to a downregulation in functional capacity, a lower quality of life, an increase in mortality, and a deterioration in lung function (9). Studies on muscle weakness suggest that the muscle quadriceps femoris weakening most rapidly in the lower extremity and that the quadriceps weakness is mortality-related in these patients (10, 11). Quadriceps muscle weakness can cause physical inactivity, increased risk of falls and fractures (12). In studies with quadriceps muscle strength and associated factors in COPD patients, there was no study investigating the relationship between kinesiophobia, quadriceps muscle strength and quality of life. Kinesiophobia is defined as anxiety about movement due to the sensation of sensitivity to pain (13, 14).

In a previous study, it was reported that in individuals with moderate-to-severe COPD, the quality of life-related factors differed between men and women (15). Women generally have more severe dyspnea symptoms than males and a lower quality of life than lung function at the same level (16). Di Marco et al. (17) reported that female patients had worse quality of life and more anxiety and depressive symptoms associated with symptoms compared to men.

The aim of this study is to examine the effect of quadriceps muscle strength and kinesiophobia on health-related quality of life in elderly women and men with chronic obstructive pulmonary disease.

## MATERIAL AND METHODS

The universe of this study was formed by volunteers (n=45) from the Bolu Abant İzzet Baysal University, Chest Diseases Polyclinic. We also did not select the sample. Prior to the study, permission was obtained from the Bolu Abant İzzet Baysal University Clinical Research and Ethics Board (Protocol number: 2016/43).

**Data collection methods:** Descriptive data were obtained from the Patient Information Form created by the researcher by searching the literature, the modified Medical Research Council Scale (mMRCs) for dyspnea, the Saint (St.) George Respiratory Questionnaire (SGRQ) for the quality of life, the TAMPA Kinesiophobia Scale (TKS) for kinesiophobia, muscle strength was assessed using hand dynamometer. Visual Analogue Scale (VAS) was used for pain. Patient demographic information (age, gender, marital status, educational status and smoking habits) was questioned by the Patient Information Form.

**mMRCs:** Dyspnea is the most common symptom of COPD failure. The level of dyspnea provides information about the patient's perception of the disease and is a measurable value. The patient expresses the degree of breathlessness between 0 and 4. It is compatible with the mMRCs health status score and other dyspnea scales and is simple to apply (18, 19).

**SGRQ:** It is a test that evaluates the health-related quality of life of individuals with respiratory diseases. It was developed in 1991 by Jones et al. (20). Polath et al. conducted validity and reliability studies in our country (21). It consists of 50 items divided into 3 fields. The symptoms consist of 8 items, the activities are 16 items and the effects of the disease are 26 items. In scoring between 0-100, 100 points to the worst health condition.

**TKS:** Kinesiophobia is defined as anxiety about movement due to the sensation of sensitivity to pain (13, 14). Developed by Miler in 1991 to measure fear of movement and/or re-injury (22). Yılmaz et al. (23) conducted validity and reliability studies in our country. The questionnaire consists of 17 questions, with a minimum score of 17 and a maximum score of 68. The high score indicates that the patient's fears are high.

**Assessment of muscle strength:** The quadriceps muscle strength of the individuals participating in the study was assessed using a hand dynamometer (Medical Commander Power Track 2, USA). The measurements were repeated three times for the right and left sides. The highest value was recorded as Newton (N) (24, 25).

**VAS:** Individuals' pain severity was assessed using VAS. VAS reliability is a demonstrated pain intensity measurement scale (26). Individuals participating in the study were told that they could evaluate their pain from 0 to 10 on a 10 cm line. It was explained that if there was no pain, 0 (the leftmost point), the most severe pain 10

(the rightmost point). According to these explanations, patients were asked to mark their pain intensity on a 10 cm line. On the 10 cm line, the patient's mark was measured with a ruler and the value found was noted as pain intensity (27).

**Statistical analysis:** Descriptive values, number, and frequencies of the obtained data were tabulated as a mean and standard deviation. The Kolmogorov-Smirnov test was used to examine whether the numerical properties were normal. Relationships between groups with categorical characteristics were examined by chi-square test. Gender differences; When the parametric test assumptions were provided, the difference between the two means was tested by the significance test, and if the assumptions were not met, the Mann Whitney U test was used. In addition, Pearson correlation analysis was used to evaluate the relationship between scale scores in each group.

Linear Regression Analysis was used in the analysis of variables with a statistically significant effect on SGRQ<sub>(Total)</sub> scores. The statistical significance level was  $p < 0.05$  and SPSS (ver. 18) program was used in the calculations.

## RESULTS

Seventeen (37.8%) of the participants were female and 28 (62.2%) were male. The mean age and body mass index (BMI) of the females were  $71.59 \pm 4.84$  years,  $28.75 \pm 6.71$  kg/m<sup>2</sup>, and the mean age and BMI of the males were  $72.14 \pm 5.66$  years and  $26.53 \pm 3.91$  kg/m<sup>2</sup>, respectively (Table 1). When the smoking status of the participating individuals was examined, 5 (29.4%) of the women and 20 (71.4%) of the men were smoking during a period of their lives. There was a statistically significant difference between male and female subjects in terms of smoking cessation in favor of male subjects ( $p < 0.05$ ).

**Table 1.** Socio-demographic characteristics of the individuals participating in the study.

	Female n=17 (x±SS)	Male n=28 (x±SS)	p
Age (year)	71.59±4.84	72.14±5.62	0.729
Body mass index (kg/m <sup>2</sup> )	28.75±6.71	26.53±3.91	0.232
	n (%)	n (%)	
Smoking status	5 (29.4)	20 (71.4)	0.000
Assistive device			
Crutch	1 (5.9)	1 (3.6)	0.274
Walking stick	5 (29.4)	4 (14.3)	
Nothing	11 (64.7)	23 (82.1)	
Marital status			
The married	8 (47.1)	24 (85.7)	0.011
Single	9 (52.9)	4 (14.3)	
Education status			
Not literate	13 (76.5)	5 (17.9)	0.000
Primary school	3 (17.6)	19 (67.9)	
Middle School	-	4 (14.3)	
High school	-	-	
University	1 (5.9)	-	
Number of hospitalizations in the last 3 months	1.60±1.63	1±0.73	0.196
FVC(%)	80.50±24.98	85.22±15.40	0.128
FEV <sub>1</sub> (%)	68.56±20.66	70.37±15.40	0.678
FEV <sub>1</sub> /FVC	72.25±6.21	71.01±7.23	0.294
PEF(%)	63.50±29.05	69.52±17.13	0.420
FEF <sub>25-75</sub> (%)	35.18±18.00	35.29±24.19	0.709
mMMRC			
mMRCS 0	1(5.9)	1(3.6)	0.196
mMRCS 1	-	8(28.6)	
mMRCS 2	4(23.5)	7(25)	
mMRCS 3	12(70.6)	12(42.9)	
mMRCS 4	-	-	
Muscle strength (N)	115.74±40.27	127.74±54.98	0.513
TKS	47.47±7.40	41.89±7.65	0.021
SGRQ			
Activity			0.263
Impact	72.49±24.79	59.69±32.86	0.146
Symptom	75.97±15.87	63.89±18.54	0.026
Total	76.53±21.18	63.72±30.43	0.104
Pain (VAS) (cm)	3.62±3.47	1.25±0.027	0.027

mMRCS: modified Medical Research Council Scale, VAS: Visual Analogue Scale, TKS: TAMPA Scale for kinesiophobia, SGRQ: St. George Respiratory Questionnaire.

**Table 2.** The relationship between kinesiophobia, pain, muscle strength and quality of life in female individuals with COPD.

		TKS	VAS	Muscle strength	SGRQ (Activity)	SGRQ (Symptom)	SGRQ (Impact)	SGRQ (Total)	PEF (%)
<b>TKS</b>	r	1	0.249	0.425	0.663	0.638	0.347	0.603	-0.503
	p		0.335	0.254	<b>0.004</b>	<b>0.006</b>	0.173	<b>0.010</b>	<b>0.047</b>
<b>VAS</b>	r		1	-0.169	0.263	0.201	0.267	0.310	-0.026
	p			0.663	0.307	0.440	0.300	0.226	0.925
<b>Muscle strength</b>	r			1	-0.820	0.318	-0.379	-0.0259	-0.417
	p				0.834	0.405	0.314	0.501	0.304
<b>SGRQ (Activity)</b>	r				1	0.230	0.586	0.864	-0.260
	p					0.374	<b>0.014</b>	<b>0.001</b>	0.925
<b>SGRQ (Symptom)</b>	r					1	0.068	0.270	-0.608
	p						0.794	0.294	<b>0.012</b>
<b>SGRQ (Impact)</b>	r						1	0.903	-0.117
	p							<b>0.001</b>	0.667
<b>SGRQ (Total)</b>	r							1	-0.157
	p								0.562
<b>PEF(%)</b>	r								1
	p								

VAS: Visual Analogue Scale, TKS: TAMPA Scale for kinesiophobia, SGRQ: St. George Respiratory Questionnaire

The SGRQ<sub>(Symptom)</sub> scores were 75.97±15.87 and 63.89±18.54 in the male and female subjects, respectively, while the TKS averages were 47.47±7.40 and 41.89±7.65, respectively. There was a significant difference between the TKS and SGRQ<sub>(Symptom)</sub> in both men and women (p<0.05). In females there was a moderate correlation between

TKS and SGRQ<sub>(Activity)</sub> (r=0.663), SGRQ<sub>(Symptom)</sub> (r=0.638) and SGRQ<sub>(Total)</sub> (r=0.603) (p<0.05) (Table 2). Similarly, there was a moderate correlation between TKS and SGRQ<sub>(Activity)</sub> (r=0.433), SGRQ<sub>(Impact)</sub> (r=0.475) and SGRQ<sub>(Total)</sub> (r=0.469) (p<0.05) (Table 3).

**Table 3.** The relationship between kinesiophobia, pain, muscle strength and quality of life in male individuals with COPD.

		TKS	VAS	Muscle strength	SGRQ (Activity)	SGRQ (Symptom)	SGRQ (Impact)	SGRQ (Total)	PEF (%)
<b>TKS</b>	r	1	-0.228	-0.516	0.433	0.321	0.475	0.469	0.028
	p		0.252	<b>0.017</b>	<b>0.021</b>	0.095	<b>0.011</b>	<b>0.012</b>	0.899
<b>VAS</b>	r		1	-0.175	-0.097	0.063	0.059	0.008	-0.038
	p			0.460	0.630	0.753	0.770	0.967	0.863
<b>Muscle strength</b>	r			1	-0.335	-0.181	-0.343	-0.346	-0.070
	p				0.137	0.433	0.128	0.125	0.790
<b>SGRQ (Activity)</b>	r				1	0.673	0.876	0.951	-0.038
	p					<b>0.001</b>	<b>0.001</b>	<b>0.001</b>	0.863
<b>SGRQ (Symptom)</b>	r					1	0.686	0.749	-0.331
	p						<b>0.001</b>	<b>0.001</b>	0.123
<b>SGRQ (Impact)</b>	r						1	0.977	-0.003
	p							<b>0.001</b>	0.988
<b>SGRQ (Total)</b>	r							1	-0.040
	p								0.855
<b>PEF(%)</b>	r								1
	p								

VAS: Visual Analogue Scale, TKS: TAMPA Scale for kinesiophobia, SGRQ: St. George Respiratory Questionnaire.

In our study, the quadriceps muscle forces of female and male individuals were 115.74±40.27 N, 127.74±54.98 N, respectively. Although the muscle strength of male individuals was higher than that of female individuals, there was no difference between muscle strengths (p>0.05).

VAS scores were 3.62±3.47 cm in female individuals and 1.25±0.027 cm in male individuals and the difference between the two gender was

significant (p<0.05). There was no correlation between VAS and quadriceps muscle strength and SGRQ parameters in both male and female subjects (p>0.05).

Compared with respiratory function test parameters and mMRCs values, there was no difference between male and female individuals (p>0.05). There was a negative moderate (r=-0.503) relationship between PEF and TKS in female

individuals, while there was a negative strong correlation between PEF and  $SGRQ_{(Symptom)}$  ( $r=-0.608$ ) ( $p<0.05$ ). FVC,  $FEV_1/FVC$ ,  $FEV_1$ , PEF,  $FEF_{25-75}$  values were not correlated with other parameters ( $p>0.05$ ).

According to the regression analysis performed (Table 4), the effect of TKS scores on  $SGRQ_{(Total)}$  scores was statistically significant in

both genders ( $p<0.05$ ). The increase in TKS score for both genders has a boosting effect on  $SGRQ_{(Total)}$  values. This effect is higher in female individuals. The effect of VAS, muscle strength and PEF percentage scores on  $SGRQ_{(Total)}$  scores was not statistically significant either in women or men ( $p>0.05$ ).

**Table 4.** The effect of pain, muscle strength, kinesiophobia and PEF(%) on the quality of life in male and female individuals with COPD.

Female	Std. Beta	t	p	%95 G.A - Lower limit	%95 G.A - Upper limit
<b>Pain (VAS)</b>	0.31	1.264	0.226	-1.297	5.073
<b>Muscle strength (N)</b>	-0.259	-0.709	0.501	-0.234	0.126
<b>TKS</b>	0.603	2.93	0.01*	0.471	2.983
<b>PEF(%)</b>	-0.157	-0.594	0.562	-0.538	0.305
Male	Std. Beta	t	p	%95 G.A - Lower limit	%95 G.A - Upper limit
<b>Pain (VAS)</b>	0.008	0.042	0.967	-4.161	4.332
<b>Muscle strength (N)</b>	-0.346	-1.607	0.125	-0.422	0.055
<b>TKS</b>	0.469	2.709	0.012*	0.45	3.283
<b>PEF(%)</b>	-0.04	-0.185	0.855	-0.879	0.735

\* $p<0.05$  statistically significant effect; Linear Regression Analysis (Dependent Variable  $SGRQ_{(Total)}$  score); Std.Beta: Standardize Beta Coefficient; 95% G.A: 95% Confidence Interval. **VAS**: Visual Analogue Scale, **TKS**: TAMPA Scale for kinesiophobia, **PEF**: Peak Expiratory Flow.

## DISCUSSION

This study has shown that kinesiophobia in individuals with COPD is more prevalent in especially female, and affects the quality of life in both genders, even more in female individuals.

One of the main causes of COPD is smoking. A study conducted in Sweden with 19750 participants found a significant increase in the risk of COPD among smokers aged 40-55 years (28). Similar to developing countries in our country, the usage rates of tobacco products have increased in recent years (29). In 2008, according to World Health Organization data rates of smoking in Turkey, it is 31.2%. In the young population, this rate reaches 40% (4). Approximately 80% of COPD-related deaths result from smoking (30).

Exercise intolerance seen in the progression of the disease is a characteristic feature of COPD (31). The power of the quadriceps femoris muscle is associated with both airflow limitation and exercise capacity (27, 32). Studies have shown that the most rapidly weakening muscle in individuals with COPD is quadriceps (6, 33, 34). Ausin et al. (35) reported that quadriceps muscle strength was lower in women with COPD compared with healthy controls in the study they performed, with greater incidence in women. Another previous study reported that quadriceps muscle endurance was significantly impaired in both genders in individuals with COPD, and muscle strength of male individuals was higher than that of female individuals (36). Hernandez et al. (37) reported that

quadriceps muscle strength was positively correlated with the level of physical activity in their study. In our study, it was observed that the muscle strength of male individuals was higher than that of female individuals, but there was no difference between muscle strengths.

Quadriceps muscle strength is an important muscle for mobility and ambulation and has a major role in gaining and maintaining physical performance. In case of weakness, the individual can go to activity restriction due to reasons such as falling anxiety and fatigue, which can adversely affect the individual's social activity participation and quality of life. For this reason, it is considered as a muscle that should be strengthened primarily in physiotherapy and rehabilitation programs. In our study, there was no statistically significant difference, but it was observed that the quadriceps muscle strength of the women was lower than the men as it was in a previous study (35). There was no correlation between quadriceps muscle strength and kinesiophobia in female individuals, but there was a significant correlation in male individuals. Our results suggest that kinesiophobia in individuals with COPD may be affected by many other factors besides muscle strength (eg, dyspnea, pulmonary system problems, etc.).

Improving the quality of life in individuals with COPD by improving the functional level is the main goal of treatment. For this reason, it is important to determine the factors affecting the

quality of life and to treat it. Benton et al. (38) reported that gender differences affect the quality of life associated with social and physical functioning in older individuals with COPD. In another study involving 430 patients, women with COPD were reported to have the significantly lower quality of life scores than men with COPD (39). Haj Ghanbari et al. (40) noted that in individuals with COPD, kinesiophobia has a significant relationship between pain, fear of movement and quality of life in their work to determine the relationship between pain and quality of life, and can also affect physical performance. Lee et al. (41) reported that the finding of pain was associated with dyspnea, fatigue and low quality of life score. The importance of interventions to reduce pain is emphasized in order to prevent negative associations of clinical symptoms in individuals with COPD (34). It has been indicated that the quality of life and functional status are significantly affected in individuals with COPD, the patients should be evaluated with objective tests and the evaluation subheadings of the scales used for evaluation may be an important guide in determining the treatment target (42). In our study, there was a positive correlation between kinesiophobia, activity participation and total quality of life in both male and female individuals, in which the health-related quality of life of the individuals was significantly associated with activity participation, disease effect and symptom and total scores. However, it was found that kinesiophobia scores in both genders affected the quality of life and this effect was higher in female subjects. When we study differently from the above-mentioned studies, no relation between the finding of pain and quality of life has been determined. However, the pain findings of the patients included in the study ranged from 1 to 3 out of 10, which was equivalent to minimal pain. In our study, it was found that the feeling of kinesiophobia was quite high, especially in female individuals. Similar to a previous study (40), it has been observed that increased kinesiophobia in individuals with COPD will affect the quality of life negatively. In another study, it was reported that pain symptoms in individuals with COPD were associated with low functional exercise capacity, decreased physical activity level and high BMI, and significantly reduced the quality of life (43). The BMI of the individuals included in the study was slightly above normal. Overweight can negatively affect the ability of the individual to move. We believe that patient education and rehabilitation programs, which can be done to control the weight of individuals with COPD and reduce the worries of fear of movement that may be experienced, will be important in increasing the quality of life.

Dyspnea, anxiety, and depression which are frequently observed in individuals with COPD can

negatively affect the lives of patients. The relationship between physical activity and anxiety in individuals with COPD has been reported in previous studies (44, 45). Anxiety, panic, and depression are common psychological disorders in individuals with COPD. In the studies conducted, the prevalence of anxiety was reported to be 10-30%, the prevalence of panic attacks 0-70% and the prevalence of depression 10-40% in individuals with COPD (24, 46). Miravittles et al. (47) reported that approximately one in five individuals with COPD were afraid of being disabled or dying because of COPD. Muscle weakness, walking, and balance disorders have been reported to increase the risk of falls 3-4 times (48). Decreased physical performance due to muscle mass loss with aging is more pronounced in chronic disease (49). There are studies in the literature showing that individuals with COPD reduce physical performance, functional capacity, and quality of life because of muscle strength loss (6, 50). These findings may have direct clinical consequences, because respiratory muscles are required for ventilation, while lower extremity muscles are necessary for daily life activities (51). However, other symptoms of the disease, such as sedentary life, pain, are thought to affect kinesiophobia (40).

Although they are at the same ventilatory insufficiency level, women have reported higher rates of dyspnea than men (16). It is also found that there is a higher correlation between dyspnea and depression in women compared to men (42). Previous studies (17, 52) reported that although they were on the same clinical level, women had higher levels of depression and anxiety than men.

In our study, it was observed that women individuals had more intense kinesiophobia than male individuals, although at the same clinical level. In individuals with COPD, physical activity levels due to dyspnea and fatigue conditions will gradually decline and individuals with COPD will increasingly adopt a sedentary lifestyle due to kinesiophobia. Especially in the beginning, out-of-home situations will be limited and over time this will start to affect the daily life activities. In elderly individuals with COPD, kinesiophobia is an important factor affecting the quality of life and is recommended to increase physical activity, physiological and emotional well-being in order to increase the quality of life in elderly individuals with COPD. This study of individuals over 65 years of age with COPD found that kinesiophobia was more prevalent among women and that kinesiophobia affected the quality of life in both sexes, more in female subjects. In this study conducted with elderly individuals with COPD, it was found that kinesiophobia was more intense in women and that kinesiophobia affect the quality of life in both genders, more in female individuals.

## REFERENCES

1. Rawal A, Girisha K. Use of Periconceptional Folic Acid for Prevention of Neural Tube Defects—Where are We. *J Obstet Gynaecol Res* 2015;41:6.
2. Varkey AB. Chronic obstructive pulmonary disease in women: exploring gender differences. *Curr Opin Pulm Med* 2004;10(2):98-103.
3. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet* 2007;370(9589):765-73.
4. Yengil E, Çevik C, Demirkıran G, et al. Tıp fakültesi öğrencilerinin sigara içme durumu ve sigara ile ilgili tutumları. *Konuralp Tıp Dergisi* 2014;6(3):1-7.
5. Ünal M. Hastanede sigara danışmanlığı: Problemler ve çözümler. *Konuralp Tıp Dergisi* 2017;9(2):171-6.
6. Swallow EB, Reyes D, Hopkinson NS, et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. *Thorax* 2007;62(2):115-20.
7. Decramer M, De Benedetto F, Del Ponte A. Systemic effects of COPD. *Lancet Respir Med* 2005;99:S3-S10.
8. Cielien N, Maes K, Gayan-Ramirez G. Musculoskeletal disorders in chronic obstructive pulmonary disease. *Biomed Res Int* 2014;2014.
9. Engelen MP, Schols AM, Does JD. Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. *Am J Clin Nutr* 2000;71(3):733-8.
10. Bernard S, Leblanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;158(2):629-34.
11. Coronell C, Orozco-Levi M, Mendez R. Relevance of assessing quadriceps endurance in patients with COPD. *Eur Respir J* 2004;24(1):129-36.
12. Beauchamp MK, Sibley KM, Lakhani B, et al. Impairments in systems underlying control of balance in COPD. *Chest* 2012;141(6):1496-503.
13. Kori S. Kinisophobia: a new view of chronic pain behaviour. *Pain Manage* 1990;3:35-43.
14. Burwinkle T, Robinson JP, Turk DC. Fear of movement: factor structure of the Tampa Scale of Kinesophobia in patients with fibromyalgia syndrome. *J Pain* 2005;6(6):384-91.
15. de Torres JP, Casanova C, Hernández C, et al. Gender associated differences in determinants of quality of life in patients with COPD: a case series study. *Health Qual Life Outcomes* 2006;4(1):72.
16. Watson L, Vestbo J, Postma DS, et al. Gender differences in the management and experience of chronic obstructive pulmonary disease. *Lancet Respir Med* 2004;98(12):1207-13.
17. Di Marco F, Verga M, Reggente M, et al. Anxiety and depression in COPD patients: The roles of gender and disease severity. *Lancet Respir Med* 2006;100(10):1767-74.
18. Stenton C. The MRC breathlessness scale. *Occup Med*. 2008;58(3):226-7.
19. Özalevli S, Uçan ES. Farklı Dispne Skalalarının kronik obstrüktif akciğer hastalığında karşılaştırılması. *Toraks Dergisi* 2004;5(2):90-4.
20. Jones PW, Quirk F, Baveystock C. The St George's respiratory questionnaire. *Lancet Respir Med* 1991;85:25-31.
21. Polatlı M, Yorgancıoğlu A, Aydemir Ö, et al. Validity and reliability of Turkish version of St. George's respiratory questionnaire. *Tuberk Toraks* 2013;61(2):81-7.
22. Miller RP, Kori SH, Todd DD. The Tampa Scale: a Measure of Kinisophobia. *Clin J Pain* 1991;7(1):51.
23. Yılmaz ÖT, Yakut Y, Uygur F. Tampa Kinezyofobi Ölçeği'nin Türkçe versiyonu ve test-tekrar test güvenilirliği. *Türk J Physiother Rehabil* 2011;22(1):44-9.
24. Bandinelli S, Benvenuti E, Del Lungo I, et al. Measuring muscular strength of the lower limbs by hand-held dynamometer: a standard protocol. *Aging Clin Exp Res* 1999;11(5):287-93.
25. Deones VL, Wiley SC, Worrell T. Assessment of quadriceps muscle performance by a hand-held dynamometer and an isokinetic dynamometer. *J Orthop Sports Phys Ther* 1994;20(6):296-301.
26. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. *Chest* 2008;134(4\_suppl):43S-56S.
27. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. *Am J Respir Crit Care Med* 1996;153(3):976-80.
28. Miravittles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. *Thorax* 2004;59(5):387-95.
29. Fidancı İ, Arslan İ, Tekin O, et al. Sigara bırakma başarısında: çay, kahve, alkol içme alışkanlıklarının, kilo alma korkusunun ve tedavi yöntemlerinin rolü. *Konuralp Tıp Dergisi* 2016;8(2):132-6.
30. General S, editor *The health consequences of smoking—50 years of progress: a report of the surgeon general*. US Department of Health and Human Services; 2014: Citeseer.
31. O'shea SD, Taylor NF, Paratz J. Peripheral muscle strength training in COPD: a systematic review. *Chest* 2004;126(3):903-14.
32. Bernard S, Leblanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;158(2):629-34.



33. Hillman C, Heinecke E, Hii J, et al. Relationship between body composition, peripheral muscle strength and functional exercise capacity in patients with severe chronic obstructive pulmonary disease. *Intern Med J* 2012;42(5):578-81.
34. Ju C, Chen R. Investigation of the quadriceps strength in patients with chronic obstructive pulmonary disease. *Chin J Tuber Resp Dis* 2008;31(8):566-70.
35. Ausín P, Martínez-Llorens J, Sabaté-Bresco M, et al. Sex differences in function and structure of the quadriceps muscle in chronic obstructive pulmonary disease patients. *Chron Respir Dis* 2017;14(2):127-39.
36. Hul AV, Harlaar J, Gosselink R, et al. Quadriceps muscle endurance in patients with chronic obstructive pulmonary disease. *Muscle Nerve* 2004;29(2):267-74.
37. Hernández M, Zambom-Ferraresi F, Cebollero P, et al. The Relationships between Muscle Power and Physical Activity in Older Men with Chronic Obstructive Pulmonary Disease. *J Aging Phys Activ* 2016:1-26.
38. Benton MJ, Alexander JL, Holland JD. Relationship between strength, function, and quality of life in older adults with chronic lung disease: is there an influence of gender? *J Cardiopulm Rehabil Prev* 2014;34(2):143-9.
39. Raherison C, Tillie-Leblond I, Prudhomme A, et al. Clinical characteristics and quality of life in women with COPD: an observational study. *BMC Womens Health* 2014;14(1):31.
40. HajGhanbari B, Holsti L, Road JD, et al. Pain in people with chronic obstructive pulmonary disease (COPD). *Respir Med* 2012;106(7):998-1005.
41. Lee AL, Harrison SL, Goldstein RS, et al. Pain and its clinical associations in individuals with COPD: a systematic review. *Chest* 2015;147(5):1246-58.
42. Reardon JZ, Lareau SC, ZuWallack R. Functional status and quality of life in chronic obstructive pulmonary disease. *Am J Med* 2006;119(10):32-7.
43. HajGhanbari B, Garland SJ, Road JD, et al. Pain and physical performance in people with COPD. *Respir Med* 2013;107(11):1692-9.
44. Anderson KL. The effect of chronic obstructive pulmonary disease on quality of life. *Res Nurs Health* 1995;18(6):547-56.
45. Kaptein A, Brand P, Dekker F, et al. Quality-of-life in a long-term multicentre trial in chronic nonspecific lung disease: assessment at baseline. The Dutch CNSLD Study Group. *Eur Respir J* 1993;6(10):1479-84.
46. Hill K, Geist R, Goldstein R, et al. Anxiety and depression in end-stage COPD. *Eur Respir J* 2008;31(3):667-77.
47. Miravittles M, Anzueto A, Legnani D, et al. Patient's perception of exacerbations of COPD—the PERCEIVE study. *Respir Med* 2007;101(3):453-60.
48. Voica AS, Oancea C, Tudorache E, et al. Chronic obstructive pulmonary disease phenotypes and balance impairment. *Int J Chron Obstruct Pulmon Dis* 2016;11:919.
49. van de Bool C, Rutten EP, Franssen FM, et al. Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD. *Eur Respir J* 2015;46(2):336-45.
50. Manguiera NM, Viegas IL, Manguiera M, et al. Correlation between clinical parameters and health-related quality of life in women with COPD. *J Bras Pneumol* 2009;35(3):248-55.
51. Gea J, Agustí A, Roca J. Pathophysiology of muscle dysfunction in COPD. *J Appl Physiol* 2013;114(9):1222-34.
52. Varol Y, Anar C, Cimen P, et al. Sex-related differences in COPD Assessment Test scores of COPD populations with or without significant anxiety and/or depression. *Turk J Med Sci* 2017;47(1):61-8.